Maxim Group analyst Michael Okunewitch maintained a Buy rating on Ocugen (OCGN – Research Report) yesterday and set a price target of $4.00.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Michael Okunewitch has given his Buy rating due to a combination of factors that highlight Ocugen’s strategic advancements and potential for significant milestones in the near future. The company is progressing with its Phase 3 pivotal study of OCU400 for retinitis pigmentosa, aiming to complete enrollment by the end of the second quarter of 2025, which sets the stage for a Biologics License Application (BLA) filing in mid-2026. This timeline is supported by the rare nature of the disease and the FDA’s priority review process, potentially leading to market entry in 2027.
Additionally, Ocugen is making strides with its OCU410 and OCU410ST programs, targeting geographic atrophy and Stargardt disease, respectively. These programs are expected to reach pivotal stages in the coming years, with BLA filings anticipated between 2027 and 2028. The company’s novel biologic, OCU200, targeting diabetic macular edema, also presents an opportunity for outlicensing, which could provide non-dilutive funding. Collectively, these developments underscore Ocugen’s potential to achieve its ambitious goal of three BLA filings within three years, starting in 2026.
According to TipRanks, Okunewitch is an analyst with an average return of -22.0% and a 28.72% success rate. Okunewitch covers the Healthcare sector, focusing on stocks such as Ocugen, Mainz Biomed B.V., and Lineage Therap.